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Objective: We wanted to prospectively assess the adverse events and hemodynamic effects associated with an intravenous 
adenosine infusion in patients with suspected or known coronary artery disease and who were undergoing cardiac MRI.
Materials and Methods: One hundred and sixty-eight patients (64 ± 9 years) received adenosine (140 µg/kg/min) during 
cardiac MRI. Before and during the administration, the heart rate, systemic blood pressure, and oxygen saturation were 
monitored using a MRI-compatible system. We documented any signs and symptoms of potential adverse events.
Results: In total, 47 out of 168 patients (28%) experienced adverse effects, which were mostly mild or moderate. In 13 
patients (8%), the adenosine infusion was discontinued due to intolerable dyspnea or chest pain. No high grade 
atrioventricular block, bronchospasm or other life-threatening adverse events occurred. The hemodynamic measurements 
showed a significant increase in the heart rate during adenosine infusion (69.3 ± 11.7 versus 82.4 ± 13.0 beats/min, 
respectively; p < 0.001). A significant but clinically irrelevant increase in oxygen saturation occurred during adenosine 
infusion (96 ± 1.9% versus 97 ± 1.3%, respectively; p < 0.001). The blood pressure did not significantly change during 
adenosine infusion (systolic: 142.8 ± 24.0 versus 140.9 ± 25.7 mmHg; diastolic: 80.2 ± 12.5 mmHg versus 78.9 ± 15.6, 
respectively).
Conclusion: This study confirms the safety of adenosine infusion during cardiac MRI. A considerable proportion of all   
patients will experience minor adverse effects and some patients will not tolerate adenosine infusion. However, all adverse 
events can be successfully managed by a radiologist. The increased heart rate during adenosine infusion highlights the 
need to individually adjust the settings according to the patient, e.g., the number of slices of myocardial perfusion 
imaging.
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INTRODUCTION
Cardiovascular magnetic resonance imaging (CMR) is 
becoming increasingly available for patients with suspected 
or known coronary artery disease. Functional imaging such 
as analysis of the myocardial perfusion or measurement 
of the coronary bypass flow reserve plays a major role in 
the assessment of these patients (1, 2). The mechanism 
and physiological consequences of pharmacological stress Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 425
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for inducing coronary hyperemia were described decades 
ago (3, 4). This now provides the basis for measuring the 
myocardial perfusion and coronary flow. 
Dipyridamole was first used as a vasodilator, but now 
adenosine is most commonly applied (5). Adenosine 
stimulates the A2A receptor on the arterial vascular smooth 
muscle cells and this causes vasorelaxation. In addition, 
the receptor sub-types named A1, A2b and A3 are stimulated 
by adenosine. These receptors also account for the potential 
adverse effects of adenosine such as dyspnea, chest pain, 
atrioventricular blockage or bronchospasm (6).
Adenosine has been validated as a safe pharmacological 
agent for myocardial scintigraphy and stress 
echocardiography (7, 8). However, its use in the context 
of MRI has to be analysed separately since the MRI 
environment could induce additional effects such as 
claustrophobia. 
The aim of this study was to investigate the tolerability 
of adenosine as a pharmacological agent in patients with 
coronary artery disease and who are undergoing CMR. We 
analysed the hemodynamic effects in terms of the potential 
significant systemic vaso-reactive reactions that could have 
an influence on the workflow or the CMR workflow.
MATERIALS AND METHODS
Patient Population 
This study was a prospectively documented case series 
involving a total of 168 patients with a mean age of 64 ± 
9 years (range: 31 to 83 years), a mean height of 173 ± 9 
cm, a mean body weight of 82 ± 15 cm and a mean body 
mass index of 27.0 ± 3.8 kg/m
2. The clinical indication 
for adenosine-based CMR was either analysis of the 
myocardial perfusion reserve in patients with suspected or 
progressive coronary artery disease or measurement of the 
coronary bypass flow reserve. The exclusion criteria were 
the typical MRI contraindications (claustrophobia, non-
compatible metallic implants, pregnancy, pacemakers) or 
contraindications to an adenosine infusion (second or third 
degree atrioventricular block, a history of clinically relevant 
asthma or bronchospasm). All patients gave us their written 
informed consent prior to the CMR examination. The local 
ethics committee approved this study. 
Cardiovascular MRI and Patient Monitoring 
Cardiovascular MRI was performed using a 1.5 Tesla MRI 
system (Magnetom Sonata Maestro Class, Siemens AG, 
Germany). For signal detection, the combination of a six-
channel body phased-array coil and a two-channel spine 
phased-array coil were used. The echocardiography (ECG)-
signal was received from an external MRI-compatible system 
(Magnitude 3150, InVivo Research Inc., Orlando, FL). Before 
and during the administration of adenosine, the heart rate, 
blood pressure and oxygen saturation were non-invasively 
measured using the same system. For the documentation 
of rhythm disturbances, the continuous ECG monitoring 
was analyzed in a qualitative manner. ECG-related adverse 
events, such as atrioventricular blocks, were noticed online 
and counted. Further, any adverse events and reasons for 
discontinuing the examination were documented.
For the myocardial perfusion studies, after the scout 
imaging and standardized determination of the heart axis 
using the cine-sequences (7), a saturation-recovery, ECG-
gated, breath-hold steady-state-free-precession (SSFP) 
perfusion sequence (TrueFISP, echo time [TE] = 1.0 ms, 
inversion time [TI] = 100 ms, a flip angle of 50°, a matrix 
of 120 x 192, a parallel imaging Grappa factor of 2, voxel 
size = 2.4 x 1.8 x 8.0 mm³, 3 slices with an acquisition 
time of 185 ms per slice, 40 repetitions) was positioned 
along the short axis at the base, centre and apex of the 
left ventricle and this allowed us to assess 16 of the 
17 segments of the American Heart Association (AHA)/
American College of Cardiology (ACC) segment model.
The contrast agent (Gadolinium-DTPA, Magnevist®, Bayer 
Schering AG, Germany) was administered into an antecubital 
vein at a flow rate of 5ml/s, and this was followed by a 30 
ml saline flush using a power injector (Injektron® 82 MRT, 
Medtron AG, Germany).
The first contrast-enhanced perfusion study was 
performed using an adenosine dosage of 0.05 mmol/kg 
without an infusion of vasodilator. The adenosine-based 
series were done 10-15 minutes after the perfusion study at 
rest. During this time, a stack of cine-SSFP short axis slices 
for the left ventricular volumetric analysis was acquired. 
Adenosine (Adenoscan®, Sanofi-Synthelabo Ltd, Berlin, 
Germany) was administered at a body weight-adapted 
infusion rate of 140 µg/kg/min for a run-in period 
of 3 minutes with using an additional venous access. 
Subsequently, during continued adenosine administration, 
two myocardial perfusion series were performed with 
different dosages of contrast agent (a low-dose of 0.05 
mmol/kg gadolimium-diethylenetriamine pentaacetic acid 
[Gd-DTPA] and a second high-dose of 0.1 mmol/kg Gd-
DTPA). The low-dose series provided a comparison with the Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 426
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rest of the imaging and subsequent semi-quantification of 
the perfusion reserve. The later high-dose series provided 
the opportunity to obtain better visual detection of 
perfusion deficits. Consequently, the overall contrast agent 
dosage was 0.2 mmol/kg Gd-DTPA for the late enhancement 
imaging. The duration of adenosine infusion for myocardial 
perfusion imaging was 6-8 minutes. Figure 1 documents a 
typical example of adenosine-based detection of coronary 
artery disease using myocardial perfusion CMR, as compared 
to that of invasive coronary angiography.
ECG-gated MR angiography and ECG-gated, breath-hold, 
phase-contrast flow mapping were performed to assess the 
flow in coronary bypass grafts (8). The typical sequence 
parameters were a TE of 4.2 ms, temporal resolution of 70 
ms, segmentation: 7, a breath-hold of approximately 20-
30 seconds, a flip angle of 30°, velocity encoding at 75 
cm/s and a voxel size of 1.4 x 0.8 x 6.0 mm
3. First, a flow 
measurement of each graft was done with the patient at 
rest followed by a second measurement during a continuous 
adenosine infusion after a run-in period of 3 minutes at 
a body weight-adapted infusion rate of 140 µg/kg/min. 
Depending on the number of bypass grafts, the overall 
duration of adenosine infusion for flow quantification 
was 5-9 minutes. Figure 2 presents a maximum intensity 
Fig. 1. Typical example of adenosine-based detection of coronary artery disease using myocardial perfusion cardiovascular MRI. 
A. Invasive coronary angiography of 71-year-old female reveals high-grade right coronary arterial stenosis (arrow). B. Perfusion deficit in 
inferior wall (arrows) is documented using short axis view of cardiovascular MRI-based perfusion imaging during adenosine infusion.
A B
Fig. 2. Usefulness of adenosine-based phase-contrast flow imaging in 68-year-old man.
A. Maximum intensity projection of contrast-enhanced MR angiography shows patient with patent left internal thoracic artery bypass 
graft (arrows) to left anterior descending coronary artery. B, C. Using adenosine-based phase-contrast flow MR imaging (B, magnitude 
image; C, phase image) (arrows), high-grade stenosis of coronary bypass graft could be detected by quantification of insufficient flow 
reserve in comparison to flow measurement with patient at rest.
A B CKorean J Radiol 12(4), Jul/Aug 2011 kjronline.org 427
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projection of a left internal thoracic artery bypass graft 
and it documents a typical example of the adenosine-based 
phase-contrast flow imaging.
Statistics
The heart rate, blood pressure and oxygen saturation 
changes were documented between when the patients 
were at rest and during the adenosine infusion. These 
variables are presented as means and standard deviations. 
Student’s paired t test was used to assess the hemodynamic 
differences at baseline and during stress MRI. Statistical 
significance was assumed for a p value < 0.05.
Any adverse events such as high-grade atrioventricular 
block are given as counts and percentages.
RESULTS
Adverse Events
Forty seven of 168 patients (28%) experienced an adverse 
event. In the majority of cases the severity of the adverse 
events was mild to moderate. All adverse events were fully 
reversible after one hour following the end of the adenosine 
infusion.
In 13 of these 47 patients, adverse events resulted in 
discontinuation of the adenosine-based measurement (8% 
of the entire study population). The most frequent reasons 
for discontinuation were intolerable dyspnea and chest 
pain. During the adenosine infusion, neither second or 
third degree atrioventricular block nor clinically relevant 
bronchospasm occurred. No life threatening adverse 
effects and no persistent or delayed adverse effects were 
observed. None of the adverse effects required treatment; in 
particular, it was not necessary to administer the antidote 
aminophylline to counteract the effects of adenosine. The 
total number of adverse effects, including those leading 
to discontinuation of the adenosine-infusion, is shown in 
Table 1.
Hemodynamic Parameters 
The heart rate significantly increased during adenosine 
infusion (69.3 ± 11.7 beats/min versus 82.4 ± 13.0 beats/
min, respectively; p < 0.001). Consequently the length 
of the cardiac cycle was significantly reduced (890 ± 
148 ms versus 748 ± 129 ms, respectively; p < 0.001). 
Fig. 3. Boxplot diagrams of diastolic (A) and systolic (B) blood pressure demonstrating no significant change before and during 
adenosine infusion.
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Table 1. Type and Frequency of Subjective Adverse 
Effects and Reasons for Interrupting Adenosine Infusion 
in 168 Patients
Adverse Effect Frequency   Discontinuation 
Any  47 (28) 13 (8)
Dyspnea 20 (12)   9 (5)
Chest pain 16 (10)   7 (4)
Headache 8 (5)   2 (1)
Abdominal pain 4 (2)   1 (0.6)
Flushing 4 (2)   0 (0)
Sore throat 4 (2)   1 (0.6)
Other 5 (3)   1 (0.6)
Note.— Numbers in parentheses are percentages.Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 428
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Oxygen saturation was slightly but significantly increased 
during adenosine infusion (96 ± 1.9% versus 97 ± 1.3%, 
respectively; p < 0.001). The blood pressure did not 
significantly change during adenosine infusion. The systolic 
blood pressure was 142.8 ± 24 mmHg before adenosine 
infusion and 140.9 ± 25.7 mmHg during the adenosine 
infusion; the diastolic blood pressure was 80.2 ± 12.5 
mmHg before adenosine infusion and 78.9 ± 15.6 during the 
adenosine infusion. Figures 3-5 present boxplot diagrams 
of the blood pressure, the blood oxygen saturation and 
the length of the cardiac cycle length during adenosine-
infusion.
DISCUSSION
This study confirms the safety of adenosine infusion 
during CMR. A considerable proportion of all patients 
(28%) will experience subjective adverse effects, but only 
a few patients (8%) will not tolerate adenosine infusion. 
However, all observed side effects in this study were not life 
threatening. A significant increase of the heart rate and the 
blood oxygen level was noticed, yet all this had no clinical 
relevance. There was no significant change in the blood 
pressure during adenosine infusion. 
During the last decade, CMR has emerged as an important 
procedure for investigating cardiovascular diseases. The 
precise morphology of the heart and the great vessels can 
be assessed without exposing the patient to radiation. 
In addition, functional CMR studies that mainly measure 
the myocardial perfusion and flow offer new non-invasive 
diagnostic possibilities in patients with suspected or known 
coronary artery disease (7-9). 
Adenosine-based myocardial perfusion CMR may be the 
preferred choice for patients with an intermediate pre-test 
probability of coronary artery disease because of its high 
diagnostic accuracy (10). In patients with known coronary 
artery disease and who have undergone bypass grafting, the 
analysis of phase-contrast MRI flow measurement allows for 
detecting high-grade stenosis in the coronary bypass grafts 
with high diagnostic accuracy (11, 12).
For both groups as described above, the assessment 
of the myocardial perfusion reserve and the bypass graft 
flow reserve is essential to induce maximal vasodilatation. 
This is usually ascertained by the administration of a 
pharmacological stress agent. Pharmacological stressors 
have a substantial advantage for MRI because physical 
exercise is impractical due to patient discomfort within the 
scanner and movement artifacts. The drugs most commonly 
used as pharmacological stressors are dobutamine, 
dipyridamole and adenosine (13).
In contrast to dobutamine, the administration of 
adenosine does not increase the myocardial oxygen 
consumption because adenosine lacks positive inotropic 
effects. In our study population, only a slight increase of 
blood oxygen saturation was observed during adenosine 
Fig. 4. Boxplot diagram shows small, but significant increase 
of blood oxygen saturation during adenosine infusion. 
This is advantageous in contrast to dobutamine, which increases 
myocardial oxygen consumption due to its positive inotropic 
effects.
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Fig. 5. Boxplot diagram demonstrates significant decrease of 
length of cardiac cycle during adenosine infusion. 
Therefore, it could be mandatory to plan to potentially tailor 
examination (e.g., reduced number of slices of myocardial 
perfusion imaging) in advance.
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infusion.
Adenosine is a more potent coronary vasodilator than 
dipyridamole (5). Peripheral venous adenosine injection 
increases the coronary flow 3 to 4 times due to a drop in 
the coronary resistance, which results in an increase in 
the myocardial blood flow (13, 14). Due to its short half-
life of less than 10 seconds, intravenous adenosine shows 
immediate effects after being started and the effects quickly 
wear off when the drug is discontinued (6). Moreover, 
the effects of adenosine can be quickly interrupted using 
aminophylline, which acts as an antidote. Usually, adenosine 
is administered as a continuous infusion for 4-6 minutes. 
A maximum duration of 6 minutes is recommended. In 
keeping with our strategy of two adenosine-based CMR 
perfusion series in the patients with up to four bypass 
grafts, we administered adenosine for a duration of up to 
8 minutes without detecting additional side effects. In our 
study, neither second nor third degree atrioventricular node 
block nor bronchospasm were observed. The administration 
of aminophylline was also not necessary.
Due to these properties and as supported by our results, 
adenosine at a dosage of 140 µg/kg/min can be considered 
as the pharmacological agent of choice for CMR myocardial 
perfusion imaging. Theoretical and practical analysis of the 
safety of adenosine also underlines that radiologists, who 
usually do not deal with such medications in their daily 
routine, will be able to manage and supervise adenosine-
based CMR examinations. 
Despite the infusion of adenosine acting as a vasodilator, 
the blood pressure showed only a minimal and statistically 
non-significant tendency to decrease. This fact was 
confirmed by other studies and this can be regarded as 
being due to a compensatory effect of the increased heart 
rate (15). The adenosine infusion resulted in a shortening 
of the cardiac cycle by 16%. Adenosine induces sympathetic 
stimulation, which is probably caused by stimulation of 
chemoreceptors in the carotid body (16). Such sympathetic 
stimulation may explain the observed increase in the heart 
rate.
The potential shortening of the cardiac cycle highlights 
the need to individually adjust the CMR parameters. An 
increased heart rate could result in a reduced number of 
slices during the adenosine infusion since 185 ms per slice 
is required in our high-resolution SSFP-perfusion sequence 
setting. 
Previous studies have been published on the adverse 
events of adenosine in the setting of CMR (15, 17, 18). 
However, those studies were only based on a small number 
of patients or on retrospective data. In our prospective 
study, 28% of the patients experienced subjective side 
effects and they mostly reported dyspnea, chest pain 
and headache. All other side effects were infrequent. 
This number of subjective adverse events was low when 
compared to that of other studies, which reported mild 
symptoms such as flushing, breathlessness or chest 
discomfort in up to 45% (15) and 63% (18) of the subjects. 
This is probably due to the selected patient populations 
with severe coronary artery disease within those previous 
studies. 
In 8% of our study population, the side effects led to 
discontinuation of the adenosine infusion, which is a 
little more frequent than that in the previous CMR studies 
(termination in less than 2%). However, our results reflect 
the safety profile shown in the perfusion studies that used 
nuclear techniques (16). These studies reported that 13% 
of the patients required a dose reduction, and in 7% the 
study was terminated before the intended time. Despite the 
different environment, there is no evidence of an increased 
number of subjective or objective adverse events when 
performing stress CMR as compared to that of the nuclear 
studies.
Limitations
The reduced ECG quality within the magnetic field and 
during the radiofrequency pulses must be considered when 
comparing our data with the data from previous nuclear 
studies. During stress CMR, the ECG quality is sufficient 
to analyze the QRS duration and the heart rate, but the 
p-wave cannot always be reliably identified. However, the 
increase of the heart rate that was noted in all patients 
demonstrates the lack of any significant atrioventricular 
conduction abnormalities. 
CONCLUSION
This study confirms the safety of adenosine infusion 
during CMR. A considerable proportion of patients will 
experience minor adverse effects, and some patients will 
not tolerate the adenosine infusion. However, a radiologist 
was able to successfully manage all observed adverse 
events. The increased heart rate during adenosine infusion 
highlights the need to adjust the settings to the individual, 
e.g., the number of slices of myocardial perfusion imaging.Korean J Radiol 12(4), Jul/Aug 2011 kjronline.org 430
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